Use of classic psychedelics may lower a person’s odds of developing opioid use disorder, said a new study published in the journal Scientific Reports.
BioSpace reviewed a busy January 5th for collaboration announcements in the life sciences world.
The U.S. Food and Drug Administration placed a clinical hold on Tryp Therapeutics’ Phase IIa trial for eating disorders, including binge eating disorder and hypothalamic obesity.
NeonMind Biosciences Inc., a psychedelic drug development company, announced the appointment of accomplished pharmaceutical executive Robert Tessarolo as President and Chief Executive Officer.